|

Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation

RECRUITINGSponsored by Herlev and Gentofte Hospital
Actively Recruiting
SponsorHerlev and Gentofte Hospital
Started2024-05-22
Est. completion2028-02-01
Eligibility
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07623473

Summary

The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule. Each blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit
* Having signed informed consent

Exclusion Criteria:

* Active cancer, excluding non-melanoma skin cancer
* Comorbidities that exclude the patient from clinical follow-up and final diagnosis

Conditions4

CancerLung CancerLung Cancer (Diagnosis)Nodule Solitary Pulmonary

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.